News from ucb A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

02 Apr, 2020, 14:34 BST UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a...


20 Feb, 2020, 06:00 GMT UCB Full Year Report 2019

7:00 (CET) – regulated information – Revenue reached € 4.9 billion (+6%, +7% CER[1]) net sales increased to € 4.7 billion (+6%) Underlying...


12 Dec, 2019, 08:00 GMT UCB: Osteoporosis Patients Believe Their Condition is Neglected and Deprioritised by Healthcare Authorities

Results from a new UCB survey have revealed the impact osteoporosis has on women, with nearly two thirds (65%) agreeing that their condition is being ...


10 Dec, 2019, 00:45 GMT UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class...


18 Oct, 2019, 06:54 BST EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN) today announced that following a re-examination procedure, the Committee for Medicinal Products ...


10 Oct, 2019, 08:37 BST UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in...


20 Sep, 2019, 16:09 BST Experts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today

- Osteoporosis is estimated to affect 200 million people worldwide1 and results in a fracture every 3 seconds2 yet a new survey reveals bone...


25 Jul, 2019, 06:00 BST UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers

– Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER1) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted2 +11%, +7% CER) ...


02 Mar, 2019, 14:29 GMT Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab - These...


28 Feb, 2019, 19:04 GMT UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline

"We are confident for the future growth of UCB based on strong delivery in 2018, marking the fifth year of profitable growth in a row and a new...


18 Oct, 2018, 06:00 BST UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful...


18 Oct, 2018, 05:01 BST The Impact of Fragility Fractures due to Osteoporosis is Being Ignored

New survey reveals that 61 per cent of women over 60 have little or no knowledge of osteoporosis,[1] despite the fact that one in three is likely to...


18 Oct, 2018, 05:01 BST The Impact of Fragility Fractures due to Osteoporosis is Being Ignored

New survey reveals that 61 per cent of women over 60 have little or no knowledge of osteoporosis,[1] despite the fact that one in three is likely to...


02 Jul, 2018, 17:30 BST UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without...


07 Jun, 2018, 06:00 BST New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases

Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) Oral presentation on CIMZIA®...


22 May, 2018, 06:00 BST UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority

Significant gaps in epilepsy management, awareness, and effective treatment access continue around the world Groups are launching a call to action...


14 May, 2018, 06:00 BST UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

- BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with...


20 Apr, 2018, 06:00 BST UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive...


05 Apr, 2018, 06:00 BST UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

Acquisition to strengthen UCB's genomics and epigenomics research platform to identify novel drug targets UCB announces the acquisition of Element...


13 Jun, 2017, 23:01 BST Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

-- First-of-its-kind CRIB study used a sensitive and specific assay designed to detect CIMZIA and found minimal to no placental transfer from mother...


25 Oct, 2016, 00:01 BST Certolizumab pegol (Cimzia®) AutoClicks® Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips® - is Now Available in the UK on the NHS[1]

UCB leads collaboration to design a prefilled pen for patients with rheumatic diseases Prefilled Pen designed for ease of use during self-injection...


10 Jun, 2016, 06:00 BST UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis

Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed...


07 Jun, 2016, 23:01 BST UCB Commitment to Addressing Real World Patient Needs on Display at the Annual European Congress of Rheumatology (EULAR 2016)

For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: An oral...


12 Nov, 2012, 09:21 GMT Have you Made a Difference to People With Epilepsy Through Journalism? - Final Call for Entries to the 2012 Excellence in Epilepsy Journalism Award

The International Bureau for Epilepsy and biopharmaceutical company UCB today issued a final call for entries to the 2012 Excellence in Epilepsy...


12 Jun, 2012, 08:00 BST Call For Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to Recognise Exceptional Reporting on Epilepsy

Today marks the launch of the 2012 Excellence in Epilepsy Journalism Award that aims to raise awareness about epilepsy across the globe. The award is ...